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http://dxBackground: The combined open surgical and endovascular approach for the treatment of aortic arch aneu-
rysms has emerged as a safe treatment modality. This platform may have an especially important role in treating
patients of old age and with a greater comorbid burden. We describe our institutional experience with the hybrid
aortic arch approach, with midterm outcomes.
Methods: From 2005 to the present, 685 patients have undergone thoracic endovascular repair (TEVAR); 104
had a hybrid arch repair (open plus endovascular approach). Of these, 47 patients had treatment for an aortic arch
aneurysm with or without a proximal ascending aortic aneurysm. All these patients had a median sternotomy
approach for arch vessel debranching and antegrade with or without retrograde TEVAR stent grafting of the
arch. Results from a prospectively maintained database are reported.
Results: Twenty-eight patients had type I repair, 8 patients had type II repair, and 11 patients had type III arch
hybrid repair. Those with type III repair were excluded from the analysis. Stent graft deployment rate was 100%
after arch vessel debranching. Mean agewas 71 8 years. Fourteen percent of cases involved a redo sternotomy.
Average cardiopulmonary bypass time was 215  64 minutes, with a crossclamp time of 70  55 minutes and
a circulatory arrest time of 19  10 minutes. The paraplegia rate was 5.5% (n ¼ 2), with a stroke rate of 8%
(n ¼ 3). In-hospital mortality was 8% (n ¼ 3). There were no postoperative endoleaks. The mean length of
stay was 17.2  14 days. The median follow-up was 30  21 months. Freedom from all-cause mortality was
71%, 60%, and 48% at 1, 3, and 5 years, respectively. The aortic reoperation rate was 2.7% (n¼ 1). No patient
has a type 1 or 3 endoleak at latest follow-up.
Conclusions: The hybrid approach to aortic arch aneurysm involving a zone 0 stent graft landing can be safely
adopted with goodmidterm results in a cohort of old patients with significant comorbidity. This procedure can be
performed with no type 1 or 3 endoleaks and may represent a technical advancement in the field of aortic arch
surgery. (J Thorac Cardiovasc Surg 2013;145:S85-90)The management of aortic arch aneurysms remains a clini-
cal challenge. Open total arch procedures can be accom-
plished using complex circulatory management and
adjunct cerebral protection, but subgroups with multiple
comorbidities may still experience significant morbidity
and mortality from both neurologic and cardiovascular
complications.1-3 In these high-risk patients, alternative
therapies are sought. The introduction and regulatory
approval of thoracic endovascular repair (TEVAR) for
descending aortic disease has seen its application to many
off-label uses, including aortic dissection,4,5 traumatice Division of Cardiovascular Surgery, University of Pennsylvania Medical
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rotic ulcers.7,8 This application has been extended to the
use of TEVAR for stenting the aortic arch with open great
vessel debranching. The ‘‘hybrid’’ aortic arch repair, with
debranching and reimplantation, or with bypass of aortic
arch vessels and TEVAR with endografting of the aortic
arch, is evolving toward a front-line treatment option for
complicated pathologic conditions of the aortic arch,9-11
especially in patients with a severe comorbid status.
Combining open surgical and endovascular techniques,
the hybrid arch repair seeks to limit operative, bypass,
and circulatory arrest times by simplifying and shortening
the arch repair. The arch hybrid concept entails reimplanta-
tion or bypass of all aortic arch vessels, and TEVAR
implantation landing proximally in ‘‘zone 0’’ (ascending
aorta–innominate origin), which is either suitable for use
as a landing zone natively or has been replaced with
a Dacron graft to construct an artificial landing zone
(Figure 1). Multiple studies have demonstrated the feasibil-
ity of this approach to the aortic arch, demonstrating accept-
able mortality and morbidity.9-11 We report our institutional
experience with the arch hybrid operation, with midterm
follow-up on these patients.diovascular Surgery c Volume 145, Number 3S S85
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CPB ¼ cardiopulmonary bypass
CTA ¼ computed tomography angiogram
NIRS ¼ near-infrared spectroscopy
TEVAR ¼ thoracic endovascular repair6 The JoMETHODS
From 2005 to the present, 685 patients have undergone TEVAR at our
institution. Of these, 104 underwent TEVAR for proximal aortic repair:
57 ascending/hemiarch replacements with antegrade stenting of the de-
scending aorta for DeBakey type I dissection and 47 hybrid arch debranch-
ing procedures. The variations of these repairs can be classified as types I,
II, and III.
Type I Hybrid Arch
Twenty-eight patients had a type I hybrid arch repair, in which there is
an isolated arch aneurysmwith good native landing zones (zone 0 and zone
3/4). Type 1 repair consists of reimplantation of the aortic arch vessels us-
ing a 4-branched Dacron graft, which is sewn to the native ascending aorta
just above the sinotubular junction (Figure 1). This can be donewithout car-
diopulmonary bypass (CPB) using a side-biting clamp in hemodynamically
stable patients if the aorta is not calcified, but it can also be done on CPB
with or without a short aortic crossclamp time.
If there is concern that the exposure of the left subclavian artery will be
difficult via a median sternotomy, a preemptive left subclavian–left com-
mon carotid bypass is an option, and only innominate and left common ca-
rotid arteries are then reimplanted into the ascending aorta. After the arch
debranching is complete, stent grafts can then be deployed via the fourth
limb of the graft into the aortic arch.12 In some patients, endograft implan-
tation is delayed and the stent graft is deployed later during the same hos-
pital stay via a retrograde iliofemoral approach. If a carotid–subclavian
bypass is performed, it is critical that the proximal left subclavian artery
be ligated or coiled to prevent a type II (branch vessel) endoleak on aortic
arch stenting. Recently, when a subclavian branch is necessary, we have
been placing it into the extrathoracic subclavian artery via the second inter-
costal space in the left side of the chest.
Type II Hybrid Arch
Eight patients underwent a type II hybrid arch repair. This is undertaken
in patients with proximal extension of aneurysmal disease into the ascend-
ing aorta, making the native aorta unsuitable for a zone 0 stent graft land-
ing. This can be addressed by replacing the ascending aorta, creating
a Dacron ascending zone 0. At our institution, ascending aorta replacement,
or a type II hybrid arch solution, is undertaken for a zone 0 diameter greater
than 3.7 cm, inasmuch as we and others have noted an increased risk of ret-
rograde type A dissection in the deployment of proximal stent grafts when
the ascending aortic diameter is greater than 4 cm.
Type II arch hybrid operations require CPB and sometimes a brief inter-
val of circulatory arrest for proximal aortic reconstruction, which can be
done using either retrograde or selective antegrade perfusion strategies. Af-
ter arch debranching and reconstruction of zone 0 with an ascending aortic
graft, the endograft can be deployed through the arch with a Dacron zone
0 landing zone.
Type III Hybrid Arch
Eleven patients underwent type 3 hybrid arch repairs: a total arch re-
placement with a descending elephant trunk, combined with a delayedurnal of Thoracic and Cardiovascular Surgsecond-stage retrograde TEVAR repair, for extensive aortic diseases such
as ‘‘mega-aorta’’ syndrome. Type 3 hybrid arch repairs are not classic hy-
brid arch repair procedures. All patients had either selective antegrade per-
fusion or a combination of antegrade and retrograde cerebral perfusion
during the circulatory arrest period. These patients are not included in fur-
ther analysis owing to significant differences in patient population, disease
process, and most important, operative technique, inasmuch as the TEVAR
solution is not into zone 0.
In all cases, the patient was deemed unsuitable for traditional open re-
pair owing to age or other comorbidities. Patients were preoperatively eval-
uated with a multislice computed tomography angiogram (CTA). CTA
images were processed into 3-dimensional images by an outside service
(M2S, West Lebanon, NH) for preoperative planning and proper sizing
of endografts deployed in the arch. Surgery was performed in the hybrid
operating room equipped with a universal floor-mounted angiographic
C-arm system for fluoroscopic guidance during and after endograft
deployment.
Intraoperative transesophageal echocardiography was used in all
cases. All patients also underwent at least one form of intraoperative neuro-
monitoring: intraoperative electroencephalogram, somtasensory-evoked
potentials, and when available, cerebral oximetry using near-infrared
spectroscopy.
Statistical Analysis and Follow-up Methods
All statistical comparisons were done using SPSS 19 (SPSS Inc, Chi-
cago, Ill). Categorical variables were compared using Fisher’s exact test.
Continuous variables were compared using the Student t test. Long-term
survival was monitored through the national Social Security Death Index
and cumulative survival was calculated using Kaplan-Meier analysis. All
patients were followed up postoperatively with regular contrast CTA imag-
ing (at discharge, 30 days, 6 months, and yearly). Follow-up was 100% in
all groups. Institutional review board approval was obtained.RESULTS
From 2005 to the present, 36 type I and II hybrid arch op-
erations were performed at the hospital of the University of
Pennsylvania. Mean age was 70.7  8 years; 23 (64%)
were male (see Table 1 for demographics). Forty-two per-
cent of the patients had prior stroke, 33% had previous
myocardial infarction, and 81% had some history of smok-
ing. Twenty-nine (81%) had aneurysmal disease of the aor-
tic arch (mean aortic diameter, 7.1  1.5 cm). Four had
chronic aortic dissection; 2 had pseudoaneurysm of the aor-
tic arch secondary to remote traumatic transection, and 1
had proximal degeneration in the setting of prior TEVAR
(for descending aortic aneurysm). Surgical history
(Table 2) included coronary artery bypass grafting
(n ¼ 3), patent foramen ovale repair (n ¼ 1), type A dissec-
tion repair via sternotomy approach (n¼ 1), and thoracoab-
dominal aortic aneurysm repair (n ¼ 1). Two patients had
prior thoracic aortic endograft repairs: 1 had proximal de-
generation of the prior repair, and 1 had a new unrelated
saccular aneurysm in the mid arch.
Of the 28 type I hybrid arch repairs, 16 (57%) were done
off CPB using a side-biting clamp on the ascending aorta for
great vessel debranching. Twelve were done on CPB, with
a mean time of 193  58 minutes and a mean aortic cross-
clamp time of 44  27 minutes. In 18 (64%) patients theery c March 2013
FIGURE 1. Hybrid aortic arch repair, types I, II, and III.
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limb of the aortic graft; 7 (25%) patients had concurrent ret-
rograde TEVAR via the iliofemoral approach. Three (11%)
patients did not have endografting during the same opera-
tion, but later in the same hospital stay using iliofemoral ac-
cess. See Table 3 for a full enumeration of the intraoperative
variables.
Eight patients did not have a suitable zone 0 for implan-
tation of a thoracic endograft. In these patients, the as-
cending aorta was replaced to create a Dacron zoneTABLE 1. Patient demographics
All hybrids Type 1 Type 2
Preoperative characteristics
N 36 28 8
Age (y) 70.7  8.0 69.3  7.5 71.1  8.3
Gender (N male) 23 (64%) 18 (64%) 5 (63%)
Prior CVA 15 (42%) 12 (43%) 3 (38%)
Chronic lung disease 14 (39%) 11 (39%) 3 (38%)
Prior MI 12 (33%) 9 (32%) 3 (38%)
Chronic renal insufficiency 6 (17%) 6 (21%) 0 (0%)
Smoker (current or history) 29 (81%) 23 (82%) 6 (75%)
Aortic disease
Aneurysm 29 (81%) 25 (89%) 5 (63%)
Maximum diameter (mean, cm) 7.1  1.5 7.1  1.5 7.4  1.4
Chronic dissection 4 (11%) 1 (4%) 3 (38%)
Failure of prior TEVAR 1 1
Pseudoaneurysm (posttraumatic
transection)
2 (6%) 2 (7%)
CVA, Cerebrovascular accident; MI, myocardial infarction; TEVAR, thoracic endo-
vascular repair.
The Journal of Thoracic and Car0 landing zone. Therefore, these patients required full
CPB and a short period of circulatory arrest for a simple
open distal anastomosis, using both antegrade and retro-
grade cerebral perfusion strategies. Mean CPB time was
259  54 minutes; mean crossclamp time was 121  63
minutes. Mean circulatory arrest time for distal anastomo-
sis was 19  10 minutes, with an additional 45  13 min-
utes of selective antegrade cerebral perfusion for arch
debranching.
Thirty-day/in-hospital mortality was 3 (8%) of 36 for the
entire group (Table 4). Mortality was 11% (n ¼ 3) in the
type I group and 0% in the type II group. Causes of death
were all secondary to neurologic complications: 2 from spi-
nal ischemia resulting in permanent paraplegia and 1 from
complications of stroke. Although there have been no in-
hospital deaths to date in patients with type II hybrid arch
repairs, mortality and all other immediate postoperativeTABLE 2. Surgical history
Surgical history All hybrids Type 1 Type 2
N 36 28 8
Redo sternotomy 5 (14%) 4 (14%) 1 (13%)
CABG 3 (8%) 2 (7%) 1 (13%)
Type A dissection repair 1 (3%) 1 (4%)
PFO closure 1 (3%) 1 (4%)
TEVAR 2 (6%) 1 (4%) 1 (13%)
TAAA 1 (3%) 1 (4%)
AAA (open or EVAR) 5 (14%) 4 (14%) 3 (38%)
CABG, Coronary artery bypass grafting; PFO, patent foramen ovale; TEVAR,
thoracic endovascular repair; TAAA, thoracoabdominal aortic aneurysm; AAA,
abdominal aortic aneurysm; EVAR, endovascular repair.
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TABLE 3. Intraoperative variables
Intraoperative All hybrids Type 1 Type 2
N 36 28 8
Off pump 16 (44%) 16 (57%)
CPB time (m) 215  64 193  58 259  54
Aortic crossclamp time (m) 70  55 44  27 121  63
Circulatory arrest 7 (19%) 7 (87%)
Circulatory arrest time (total, m) 19  10
SACP time for arch debranching (m) 45.0  13
Number of stents implanted (median) 2 2 1.5
Adjunct CABG 7 (19%) 6 (21%) 1 (13%)
Adjunct valve repair/replace 2 (6%) 1 (4%) 1 (13%)
Two-branch reimplantation with
carotid–left subclavian bypass
8 (22%) 7 (25%) 1 (13%)
CPB, Cardiopulmonary bypass; SACP, selective antegrade cerebral perfusion;CABG,
coronary artery bypass grafting.
FIGURE 2. Midterm follow-up outcomes in type I and type II hybrids.
Mean follow-up, 30 21 months. Late stroke and endoleak rate, 0%. Aor-
tic reoperation rate, 2.7%.
Panel 2 Bavaria et aloutcomes showed no significant difference between the 2
hybrid arch types (Table 4). Two (6%) of 36 patients had
permanent paraplegia/paraparesis postoperatively, with
an additional 5 (14%) of 36 having mild fully reversed
transient neurologic events. Importantly, both cases of per-
manent paraplegia occurred during the first year of adopting
this surgical modality.
Late type 2 endoleak (branch vessel) occurred in 1 pa-
tient, noted 3 years postoperatively. This patient had
a type 1 hybrid arch repair for proximal degeneration of
a prior TEVAR repair (with additional distal TEVAR for
a distal type 1 endoleak in the same operation) and did
not have full relining of the prior endograft repair. This pa-
tient did not undergo reintervention and died 6 years after
the operation.
Follow-up was 30  21 months. Late freedom from all-
cause mortality was 71%, 60%, and 48% at 1, 3, and 5
years (N at risk¼ 22, 10, and 4), with 16 late patient deaths:
all but 1 occurred in the type 1 hybrid group (Figure 2).
Cumulative survival at 1 year for type II hybrids was
87% (N at risk ¼ 3), better than type I hybrids (68%; NTABLE 4. Postoperative outcomes
Outcomes All hybrids Type 1 Type 2
P (type 1
vs type 2)
N 36 28 8
In-hospital mortality 3 (8%) 3 (11%) 0 .45
Stroke 3 (8%) 3 (11%) 0 .45
Permanent paraplegia 2 (6%) 2 (7%) 0 .6
Transient heurologic
deficit
5 (14%) 3 (11%) 2 (25%) .3
Renal failure 3 (8%) 3 (11%) 0 .45
Renal failure requiring
new hemodialysis
1 (3%) 1 (4%) 0 .78
Reoperation for bleeding 1 (3%) 1 (4%) 0 .78
Atrial fibrillation 15 (42%) 11 (39%) 4 (50%) .44
Mean hospital stay (d) 17.2  14.0 16.3  14.0 22.0  9.6 .28
S88 The Journal of Thoracic and Cardiovascular Surgat risk ¼ 19). Again, this difference did not rise to the level
of statistical significance (P¼ .244). The aortic reoperation
rate was 1 (2.8%) of 35: 1 patient required a reintervention
for a retrograde type A dissection 155 days after a type I
hybrid repair; the second repair was tolerated with no
complications. Importantly, this single retrograde type A
dissection was with a 42-mm barbed endograft for an as-
cending aortic diameter larger than 38 mm, which in our
present algorithm is contraindicated unless a type II repair
is performed.
DISCUSSION
Hybrid approaches for the treatment of aortic arch aneu-
rysmal disease are being performed with increasing fre-
quency. This is a reflection of the increasing comfort level
of cardiovascular surgeons with endovascular technology
and the improving technology of endovascular platforms,
which permit successful landing of stent grafts in the prox-
imal thoracic aorta. As the technology improves, it will be
critical for the cardiovascular surgeon to be trained in ad-
vancing the field of hybrid aortic arch and ascending aorta
operations. In addition, as the patient population with tho-
racic aortic disease seeking intervention gets older and
older, embracing and honing these skills will be crucial. Al-
though there is mounting evidence to suggest an important
role for the hybrid approach for treating aortic arch disease,
to this day there are no randomized trials or large non-
randomized studies comparing hybrid arch procedures
with conventional open surgical approaches. Interpretation
of what data exist must be viewed in this context.
In addition to the operative mortality associated with
complex operations such as aortic arch hybrid procedures,
the Achilles heel of this intervention remains neurologic
complications. Several groups have shown that arch hybrid
procedures can be performed with acceptable mortality,
with a very minimal postoperative and long-term endoleakery c March 2013
Bavaria et al Panel 2rate.9-11,13-16 However, neurologic complications, including
stroke and spinal cord ischemia, remain a significant
cause of morbidity and associated mortality in this cohort
of patients. In a systematic review of hybrid arch
operations in 1886 patients, pooled mortality was 10.8%,
with 15.1% mortality in diseases that extended to the
ascending aorta.13 Pooled stroke risk was 7%, with a pooled
spinal cord ischemia rate of 7%, with no difference seen
with respect to the extent of proximal ascending aortic in-
volvement. In our series of 36 patients, mortality was 8%
(n¼ 3), with all deaths seen in the type I hybrid arch group.
Eight patients undergoing type II hybrid repair had no
mortality.
The stroke rate was 8%, with a paraplegia rate of 5.5%.
All 3 deaths in the cohort had associated neurologic compli-
cations (2 with paraplegia; 1 with stroke), underlying the
significant morbidity and mortality associated with these
devastating complications in aortic arch surgery. Of note,
42% of the patients in our study had a preoperative history
of stroke. Twenty-nine of the 36 patients had atherosclerotic
aneurysms, with 52% of the patients having high-grade ath-
eroma or mobile atheroma. Atherosclerotic disease is a pre-
dictor of perioperative stroke, and the large cohort of
patients with prior stroke and high-grade atheroma attests
to the level of comorbid status in the arch hybrid group.17,18
When we compared our arch hybrid and open surgical arch
cohorts, the rate of high-grade (grade  3) or mobile ather-
oma was significantly higher in the hybrid group (48%
vs 6%). Several groups report stroke rates up to 12% in
patients undergoing total arch repair of atherosclerotic
aneurysms.3,11,17-19 Our study, in addition to others,
suggests that the hybrid arch approach to atherosclerotic
aneurysmal arch disease can be safely adopted with
neurologic outcomes at least equivalent to those of
conventional open repair.
A complication unique to the hybrid aortic arch cohort of
patients, unlike the conventional open group, is the occur-
rence of endoleak. The reporting of endoleak rates with
hybrid arch repair is not very thorough, with long-term fol-
low-up data virtually absent. Endoleak rates have ranged
from 0% to 15%.9-12,16-18 Similar to TEVAR, hybrid arch
operations with type I and III endoleaks are associated
with greater morbidity than those seen with type II
endoleaks. In an article by Kotelis and associates,14 patients
undergoing hybrid arch repair with zone 0 proximal landing
had lower endoleak rates than with zone 1 landing. At our
institution, we do not perform zone 1 proximal landing.
All arch aneurysms are treated with zone 0 landing. In
this study, the intraoperative endoleak rate was 5 (13.8%)
of 36. All these patients underwent further endovascular re-
intervention with a resulting postoperative endoleak rate of
0%. On late follow-up, 1 patient had a retrograde type A
dissection develop from the proximal landing zone site.
This case was undertaken during our fourth year of archThe Journal of Thoracic and Carhybrid operations, with the use of a TX2 device (CookMed-
ical, Bloomington, Ind). After this experience, we have
stopped using the TX2 stent graft device for arch hybrid op-
erations. We have adopted primarily the use of the Gore
TAG device (W. L. Gore & Associates, Inc, Flagstaff,
Ariz) and at times the Valiant device (Medtronic, Inc, Min-
neapolis, Minn). Since this switch, we have not had a retro-
grade type A dissection, and we have had no distal type B
dissections in the arch aneurysm cases. In other series, in
patients with endoleak, the aortic reoperation rate is in-
creased. Our aortic reoperation rate is 1 (2.7%) of 36
(a retrograde type A dissection with the use of the TX2 de-
vice proximally) during the median midterm follow-up of
30 months.
Eight patients in this study underwent type II arch hybrid
repair. Owing to the required ascending aortic reconstruc-
tion, all these patients had a period of circulatory arrest.
Even though these patients had a more complex operation,
postoperative and midterm outcomes in these patients have
been excellent. Postoperative mortality, stroke, paraplegia,
and endoleak rates were all 0%. One patient died during
follow-up. Inasmuch as these cases were performed more
recently, this may be a reflection of the increasing experi-
ence we gained with the hybrid arch platform. In line with
this idea, since our first year of hybrid arch operations,
the paraplegia and aortic reoperation rates have remained
at 0% in the type I arch hybrid group as well, with a single
postoperative death since then.CONCLUSIONS
The hybrid approach to the treatment of aortic arch aneu-
rysm continues to evolve, with an increasingly important
role especially in patients with a high comorbid index and
old age. On the basis of the arch and ascending aortic anat-
omy, this procedure can be performed without CPB. Mid-
term follow-up on these patients has shown that the
technique can be safely adopted with a low aortic reopera-
tion rate and with no delayed stroke and endoleak. The type
II arch hybrid, which involves greater complexity, can also
be safely adopted with good midterm outcomes. Further
follow-up will attest to the validity of this technique in
aortic arch surgery.References
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